

BIOCRYST PHARMACEUTICALS INC
 Form 4
 June 22, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 STAAB THOMAS R II

2. Issuer Name and Ticker or Trading Symbol
 BIOCRYST PHARMACEUTICALS INC [BCRX]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 4505 EMPEROR BLVD., SUITE 200
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 06/18/2015

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 Senior Vice President and CFO

DURHAM, NC 27703

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock ⁽¹⁾	06/18/2015		S	3,500	D \$ 14	149,644	D
Common Stock ⁽¹⁾	06/18/2015		M	3,100	A \$ 3.78	152,744	D
Common Stock ⁽¹⁾	06/18/2015		M	3,100	A \$ 3.78	155,844	D
Common Stock ⁽¹⁾	06/18/2015		S	3,100	D \$ 14.25	152,744	D
Common Stock ⁽¹⁾	06/18/2015		S	3,100	D \$ 13.5	149,644	D

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Common Stock <u>(1)</u>	06/19/2015	S	3,500	D	\$ 15	146,144	D
Common Stock <u>(1)</u>	06/19/2015	M	3,175	A	\$ 3.78	149,319	D
Common Stock <u>(1)</u>	06/19/2015	S	3,175	D	\$ 15	146,144	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (Right to Buy) <u>(1)</u>	\$ 3.78	06/18/2015		M	3,100	07/01/2012 07/01/2021	Common Stock	3,100
Stock Option (Right to Buy) <u>(1)</u>	\$ 3.78	06/18/2015		M	3,100	07/01/2012 07/01/2021	Common Stock	3,100
Stock Option (Right to Buy) <u>(1)</u>	\$ 3.78	06/19/2015		M	3,175	07/01/2012 07/01/2021	Common Stock	3,175

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
			Senior Vice President and CFO	

STAAB THOMAS R II
4505 EMPEROR BLVD.
SUITE 200
DURHAM, NC 27703

Signatures

/s/ Alane P. Barnes, by power of
attorney

06/22/2015

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.